The identification of new therapies for high-risk (HR) hepatoblastoma is challenging. Children's Oncology Group study AHEP0731 included a HR stratum to explore the efficacy of novel agents. Herein, the authors report the response rate to the combination of vincristine (V) and irinotecan (I) and the outcome of patients with high-risk hepatoblastoma. METHODS: Patients with newly diagnosed metastatic hepatoblastoma or those with a serum a-fetoprotein (AFP) level <100 ng/mL were eligible. Patients received 2 cycles of V at a dose of 1.5 mg/m 2 /day intravenously on days 1 and 8 and I at a dose of 50 mg/m 2 /day intravenously on days 1 to 5. Patients were defined as responders if they had either a 30% decrease in tumor burden according to Response Evaluation Criteria In Solid Tumors (RECIST) or a 90% (>1 log 10 ) decline in their AFP level. Responders were to receive 2 additional cycles of VI intermixed with 6 cycles of the combination of cisplatin, doxorubicin, 5-fluorouracil, and vincristine (C5VD). Nonresponders were to receive 6 cycles of C5VD alone. RESULTS: A total of 32 patients with a median age at diagnosis of 26 months (range, 11-159 months) were enrolled between September 2009 and February 2012. Fourteen of 30 evaluable patients were responders (RECIST and AFP in 6 patients, RECIST only in 3 patients, and AFP only in 5 patients). The median AFP decline after 2 cycles of VI for the entire group was 345,565 ng/mL (85% of the initial AFP). The 3-year event-free and overall survival rates were 49% (95% confidence interval, 30%-65%) and 62% (95% confidence interval, 42%-77%), respectively. CONCLUSIONS: The VI combination appears to have substantial activity against HR hepatoblastoma. The ultimate impact of this regimen in improving the outcomes of children with HR hepatoblastoma remains to be determined.
INTRODUCTION
In children with hepatoblastoma (HB), those with metastatic disease or low serum a-fetoprotein levels (AFP) at the time of diagnosis have the worst prognosis, with an event-free survival (EFS) rate of <50%. [1] [2] [3] [4] Over the last several decades, the outcomes for these patients have not appeared to improve significantly.
Recently, the International Childhood Liver Tumors Strategy Group (SIOPEL) demonstrated improved survival in high-risk patients using an intensified schedule of cisplatin and doxorubicin. 10 However, the significant toxicities associated with these 2 agents limit the cumulative doses that can be administered. Therefore, there continues to be a need to identify novel agents that can improve survival and minimize late effects for these high-risk patients.
Irinotecan (I) is a topoisomerase I inhibitor with a wide range of antitumor activity in human tumor xenografts and has been tested in several phase 1 and 2 pediatric trials in different dosing schedules and combinations. 11, 12 In these studies, one patient with HB achieved a complete response (CR) and another had a 1-log reduction in their AFP level and stable disease as determined on imaging. 13, 14 Case reports also have suggested that I may be associated with a good response in patients with HB. 15 Recently, a SIOPEL trial using single-agent I administered in a 5 days 3 2 weeks cycle demonstrated partial responses (PRs) by AFP level or Response Evaluation Criteria In Solid Tumors (RECIST) in 6 of 24 patients with recurrent and refractory disease. 16 The optimal method for assessing response to novel agents is debatable and perhaps somewhat controversial. Traditionally, RECIST criteria have been used but are limited to measuring tumors in a single dimension. 17, 18 Furthermore, radiographic response, or the lack thereof, does not necessarily correlate with intracellular events within the tumor. Ideally, biologic markers, such as AFP, should be a more reliable indicator of the efficacy of a novel agent or therapy. In a seminal article by Van Tornout et al, a decline in serum AFP of 90% (1 log 10 ) over an average of 6 cycles of therapy was shown to be associated with better outcome in a small cohort of patients with HB. 19 However, to the best of our knowledge, since the initial publication of this study >20 years ago, little has been done to further investigate the power of an AFP decline to predict outcome or to guide risk-based therapy. 3, 20 The Children's Oncology Group Study for the Treatment of Children with All Stages of Hepatoblastoma (AHEP0731) included a stratum to explore the efficacy of innovative chemotherapy for high-risk patients. Herein, we report the response rate of 2 cycles of vincristine (V) and I (VI) administered in an upfront window to children newly diagnosed with high-risk HB.
MATERIALS AND METHODS

Study Patients
Patients with newly diagnosed, previously untreated HB were eligible for high-risk window chemotherapy if they had either metastatic disease or a serum AFP level of <100 ng/mL at the time of diagnosis, irrespective of stage of disease. The National Cancer Institute, the Pediatric Central Institutional Review Board, and the Institutional Review Boards of the participating institutions approved the protocol. Informed consent was obtained for all patients before treatment. This study is registered at ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT00980460).
Staging
Patients were staged for risk classification using the Children's Oncology Group staging guidelines 6 before the initiation of chemotherapy, with stage IV indicating metastatic disease. Pretreatment extent of disease (PRE-TEXT) 21 grouping also was performed at the time of diagnosis and with any subsequent abdominal computed tomography (CT) or magnetic resonance imaging (MRI) ( Fig. 1 ) and was used to guide the surgical management, but was not used for risk classification. All diagnostic and follow-up imaging were centrally reviewed.
Chemotherapy
Patients received V at a dose of 1.5 mg/m 2 /day (0.05 mg/ kg/day) intravenously on days 1 and 8 with I at a dose of 50 mg/m 2 /day (1.67 mg/kg for patients weighing <10 kg) intravenously over 90 minutes on days 1 to 5 in combination (Fig. 2) . Repeat imaging and AFP measurements were performed after 2 cycles to assess response to VI. Patients who were considered responders according to institutional assessment received 2 additional cycles of VI intermixed with 6 cycles of cisplatin (at a dose of 100 mg/m 2 /dose or 3.3 mg/kg/dose for those weighing <10 kg) intravenously over 6 hours on day 1; doxorubicin (at a dose of 30 mg/m 2 / dose or 1 mg/kg/dose for those weighing <10 kg) intravenously over 15 minutes on days 1 and 2; 5-fluorouracil (at a dose of 600 mg/m 2 /dose or 20 mg/kg/dose for those weighing <10 kg) as an intravenous push on day 2; and vincristine (at a dose of 1.5 mg/m 2 /day or 0.05 mg/kg/day) as an intravenous push on days 2, 9, and 16 (C5VD). Dexrazoxane (at a dose of 300 mg/m2/dose or 10 mg/kg/dose for patients weighing <10 kg) as an intravenous push was given before doxorubicin during the last 2 cycles of C5VD. All cycles lasted 21 days. Patients who were nonresponders received 6 cycles of C5VD without further VI.
Surgery
Study patients could undergo primary tumor resection at any point during therapy, either by surgical resection or total hepatectomy followed by orthotopic liver transplantation. This was to optimally occur per protocol after cycle 7 of 10 in responders or after cycle 6 of 8 in nonresponders. Metastatic lesions were to be addressed surgically at the discretion of the treating physicians.
Pathology
Central pathologic review was performed for all biopsied and resected specimens (liver and/or lung) to assess tumor histology.
Toxicity
The individual occurrences of toxicities were graded according to National Cancer Institute Common Toxicity Criteria (version 3/4) guidelines. The frequency of each type of toxicity was quantified as the number of patients during a reporting period for whom the toxicity of the relevant grade was reported.
Evaluation of Response
Baseline physical examinations, organ function, AFP levels, and imaging studies (including a CT scan or MRI of the abdomen, ultrasound of the liver, and CT scan of the chest) were performed before the initiation of therapy. Repeat imaging studies (CT scan or MRI of the abdomen) were performed after 2 cycles of VI and then after every 2 cycles of C5VD. AFP levels were obtained before the beginning of each cycle.
For enrollment, metastatic disease was determined by imaging assessment and/or biopsy at the treating institution. The definition of metastatic disease was the clinical impression of the treating institution regarding whether a pulmonary lesion was metastatic HB. For this trial, pulmonary lesions did not need to be biopsied or of a certain size or number to be considered as disease. All patient responses were assessed by the institutional investigator and used to assign subsequent protocol therapy. RECIST and AFP response for the purposes of the efficacy assessment were obtained from central review. Two study radiologists (M.H.M. and A.J.T.) independently assessed imaging and determined overall response for all patients using RECIST criteria. 18 Agreement on response assignment between the 2 radiologists was required for the purposes of the current study and discrepancies were resolved by consensus review. Response also was assessed using decline in serum AFP levels. The AFP decline during the initial window period was determined using the maximum AFP before the initiation of chemotherapy and the AFP before the initiation of cycle 3.
For the purposes of the current study, a CR was considered to be the disappearance of all lesions and a normal AFP level. A PR was considered to be either: 1) a 30% decrease according to RECIST; or 2) a serum AFP level concentration decline of 90% (1 log 10 ) after 2 VI cycles in the absence of disease progression.
Statistical Design and Analysis
To be considered for the evaluation of VI, patients were required to have measurable disease according to RECIST 18 at the time of study enrollment and AFP before the initiation of chemotherapy. The endpoint efficacy assessment was disease status at the end of 2 cycles of therapy. Patients were considered evaluable if the individual met eligibility criteria and received at least 1 dose of each agent in the combination being tested. Any evaluable patient who achieved a CR or PR during the first 2 cycles was considered a responder and this was the primary statistical endpoint. An increase in AFP alone was not considered evidence of progressive disease. All other evaluable patients were considered to be nonresponders.
Patients were to be enrolled in 2 stages of 15 evaluable patients each. If, at the end of the first stage, 4 patients were considered responders or 6 patients experienced early disease progression, enrollment was to be halted with the conclusion that the combination of VI did not provide sufficient disease control. Early disease progression was defined as an increase in RECIST-measureable disease size of 20% or the documentation of new lesions before the end of 2 cycles of VI. If 30 patients were enrolled and 14 patients demonstrated a response, the data would not be considered consistent with a true response rate of 50%, which is the target described in the protocol as sufficient to warrant the further development of VI.
Survival EFS was measured from the time of patient enrollment until the last follow-up or when an analytic event was observed, whichever occurred first. 22 Analytic events were: 1) progression of disease or occurrence of disease at new sites; 2) treatment failure, defined as the presence of disease after planned chemotherapy; 3) death from any cause before disease progression; or 4) the diagnosis of a second malignancy. Overall survival was defined from the time of study enrollment until death from any cause or last follow-up, whichever came first. Time of surgical excision of the primary tumor was identified as the cycle during which nonliver transplantation excision of the primary tumor or liver transplantation of the primary tumor was attempted.
The percentage of patients who were event free as a function of time since study enrollment or at the end of 2 cycles of VI, as appropriate, was estimated by the KaplanMeier method. 22 The 95% confidence intervals (95% CIs) were estimated using the log-log transformation. Differences for risk of an EFS event according to attained RECIST and attained AFP response were assessed using a 2-sided log-rank test 23 from the end of the cycle 2 evaluation. A P .05 was to be considered indicative of a significant relationship.
RESULTS
A total of 32 patients were enrolled on the study between September 2009 and February 2012. Outcome current to June 30, 2014 was used in the current analysis. One patient was deemed ineligible due to inadequate organ function. A second patient was deemed nonevaluable for window response because an accurate AFP level was not obtained before the initiation of chemotherapy. The remaining 30 patients were the subject of the current report. All patients had metastatic disease and no patient had an AFP level <100 ng/mL at the time of diagnosis. The median age of the patients at the time of diagnosis was 26 months (range, 11-159 months) ( Table 1 ). There were 18 male and 12 female patients. The median AFP at the time of diagnosis was 397,748 ng/mL (range, 36,300-5,036,000 ng/mL). The median duration of follow-up for EFS for those without an EFS event was 38 months.
Response
Fourteen of 30 patients were responders according to study criteria (both RECIST and AFP in 6 patients, RECIST only in 3 patients, and AFP only in 5 patients) ( Table 2 ). Four patients demonstrated in increase in their initial AFP level from the time of study enrollment to the end of cycle 2. The median AFP decline after 2 cycles of VI for all patients was 85% (Fig. 3) . The median decline in RECIST after 2 cycles of VI was 18% (Fig. 4) . No patient experienced early disease progression. Only 9 patients (30%) had metastatic lesions considered measurable by RECIST. A detailed report regarding the characteristics, number, size, and response of pulmonary lesions will be reported separately. AFP decline following the first two cycles of VI was not predictive of outcome ( Figure 5) . Patients who had a partial AFP response had three-year EFS of 36% (95% CI: 11%-63%) compared to 56% (95% CI: 31%-75%) in no1n2-responders (p 5 0.46). Response according to RECIST also was not found to be predictive of outcome because responders had a 3-year EFS rate of 44% (95% CI, 14%-72%) compared with 51% among nonresponders (95% CI, 28%-70%) (P 5 .98). Of the 7 patients who had an increase in tumor size after the 2 cycles of upfront window chemotherapy, all had an increase of <20%, which was the criteria for progressive disease. Only 2 of these patients had an increase in their AFP level, whereas the remaining patients had decreases in AFP ranging from 8% to 92%.
PRETEXT Risk Stratification and Surgery
All but one patient underwent an initial biopsy and 3 patients underwent an upfront biopsy of lung metastases. A total of 21 patients (70%) were able to undergo a tumor resection while receiving protocol therapy, including 5 patients who underwent a liver transplantation (Table 3) , and 10 patients underwent resection of pulmonary metastatic disease during protocol therapy (detailed results to be reported separately). PRETEXT staging was stage II in 9 patients, stage III in 7 patients, and stage IV in 14 patients. Fourteen patients (1 with PRETEXT stage II, 3 with PRETEXT stage III, and 10 with PRETEXT stage IV) were downstaged with regard to their PRETEXT grouping before surgery, 9 patients were downstaged after cycle 2, 4 patients were downstaged after cycle 4, and 1 patient was downstaged after cycle 7.
Outcome
The 3-year EFS rate for the 30 patients who were evaluable for response was 49% (95% CI, 30%-65%), whereas the 3-year survival rate was 62% (95% CI, 42%-77%) (Fig. 6) . Two patients died without disease recurrence while receiving therapy, 1 patient had a cardiac arrest after a gastrointestinal procedure, and another patient died of postresection complications. A total of 13 patients developed disease recurrence. The sites of recurrence were pulmonary alone in 7 patients; liver alone in 1 patient; combined pulmonary and liver recurrence in 3 patients; combined bone and liver in 1 patient; and combined liver, bone, and lymph nodes in 1 patient. The age distribution precluded any determination of differences in outcome.
Pathology
Histology of the tumor at the time of study enrollment was centrally reviewed in 28 of 30 patients. Tumors from 5 patients were noted on central review to have small cell undifferentiated elements at the time of diagnosis ranging from 1% to 10%. All retained INI1 immunohistochemical staining and will be detailed in a separate report.
Toxicities
The most common grade 3 and grade 4 toxicities during the first 2 cycles of chemotherapy were diarrhea (8 patients), anorexia (7 patients), febrile neutropenia (7 patients), nausea (6 patients), and a documented infection (4 patients) ( Table 4) . Neuropathy was only reported in 1 patient (3.3%). Fourteen patients (47%) had febrile neutropenia and an infection occurred in 10 patients during the first 2 cycles of C5VD.
DISCUSSION
The AHEP0731 trial included a high-risk stratum to explore the usefulness of novel agents in an upfront therapeutic window. We observed a favorable response to VI in 14 of 30 patients (47%). Eleven patients (37%) experienced a 90% decline in AFP after the first 2 cycles of VI and therefore were considered to be AFP responders according to study criteria. However, an additional group of 15 patients had some decrease in AFP (7%-89%) in response to VI (Table 2) (Fig. 3) , with an overall median decline of 85%. We believe that this demonstrates definitive activity of VI against HB in a group of untreated, newly diagnosed patients with metastatic disease, particularly when considering that the study criteria were based on an assessment tool previously used to evaluate outcome and not efficacy in patients who received a much longer course of treatment (averaging 6 cycles of therapy).
A recent report from SIOPEL that investigated the use of single-agent I for patients with recurrent HB was stopped early due to meeting the criteria for a positive treatment effect, with 2 patients having a response observed by AFP decline only, 1 having a response detected by RECIST only, and 1 patient who had both a RECIST and AFP response for an overall AFP response rate of 17% in this cohort of patients with recurrent disease. 16 The EFS rate of 49% may be better than what has been described previously, although it is less than a recent SIOPEL 4 report. 10, 24 A direct comparison of outcome data is difficult because of the small patient numbers and the fact that the primary objective of the current study was the identification of novel agents with antitumor activity rather than outcome. We believe that monitoring AFP levels by percentage decline rather than logarithmically should be used going forward for simplicity.
It is interesting to note that no patient in the current trial had a low AFP level at the time of diagnosis. A small component (1%-10%) of small cell undifferentiated elements was observed in 5 patients by central review at diagnosis. Treatment with VI was found to be well tolerated. Diarrhea was the most frequent complication, occurring in 26% of patients, which is similar to other previously reported trials. 25 Although febrile neutropenia occurred in nearly 23% of patients, this toxicity during the VI cycles was less than that observed during the C5VD cycles. Although cardiac toxicity was observed in 2 patients, it should be noted that 1 case occurred in proximity to a gastrointestinal procedure not directly related to HB therapy and the other took place during surgical resection.
To the best of our knowledge, the current study is one of the few trials to date in pediatric oncology that has used a biomarker as evidence of therapeutic activity. Some patients responded by RECIST only, some by AFP only, and some by both criteria, but a decline in AFP identified the largest number of responsive patients. The ease of AFP determination makes it a tool that could be used routinely to evaluate therapeutic efficacy. Although only 11 patients in the current study met our predetermined definition of AFP response, 26 patients demonstrated some reduction in AFP after therapy with VI.
These results highlight the importance of using the appropriate assessment tools to ensure that a potentially active regimen is not discarded. In the current study, VI would be discarded based on our predetermined criteria. However, a closer examination of the data suggests that this regimen still holds promise and warrants further study. Use of the 90% decline (1 log 10 ) as a marker of therapeutic efficacy was based on the article by Van Tornout et al from >20 years ago that used AFP as a prognostic marker over a 6-cycle/18-week period. 19 This trial used the 90% decline as a marker of efficacy over only 2 cycles. Perhaps our error was using AFP prognostic criteria to evaluate efficacy. SIOPEL trials often have used any AFP decline as an indicator of response. It also is important to note that RECIST response did not correlate with outcome either. The role of VI in subsequent liver trials remains to be determined. The current study was not intended or powered to assess the impact on outcome, and this should be studied through a randomized clinical trial. Due to the limitations on total deliverable cisplatin and doxorubicin, VI is attractive as a less toxic alternative. There are reports of the use of VI for maintenance therapy in patients with minimal residual disease. 15 Patients with high-risk metastatic disease would appear to be ideal patients in whom to test the benefit of maintenance therapy.
Although the VI regimen did not meet predetermined criteria for demonstrating sufficient disease control, a closer examination of the percentage decline in serum AFP levels demonstrated that VI did appear to have activity in a large group of newly diagnosed patients with high-risk HB. The current study results suggest that further exploration of this combination is warranted. The use of AFP as a biomarker is important for any subsequent study examining patients with HB, and further study is needed to evaluate how the percentage decline of AFP can best be used to predict treatment efficacy. 
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